Remimazolam besylateProduct ingredient for Remimazolam

Remimazolam is an ultra short-acting benzodiazepine used in the induction and maintenance of sedation during short (<30 minute) procedures.⁶ Recent trends in anesthesia-related drug development have touted the benefits of so-called "soft drugs" - these agents, such as remifentanil, are designed to be metabolically fragile and thus susceptible to rapid biotransformation and elimination as inactive metabolites.⁴ These "soft drugs" are useful in the context of surgical procedures, wherein a rapid onset/offset is desirable, enabling anesthesiologists to manipulate drug concentrations as needed.^3,4 Remimazolam was the first "soft" benzodiazepine analog to be developed⁵ and was approved for use by the FDA in July 2020 under the brand name Byfavo.⁷